Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

Background: Since its introduction, palivizumab has been used to prevent respiratory syncytial virus (RSV) infection in high-risk populations. Recommendations for palivizumab administration ...

Get detailed information on Palivizumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Merck (NYSE:MRK) also announced interim data from a Phase 3 trial testing clesrovimab against RSV therapy palivizumab in ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...